Compare Natco Pharma with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs SUVEN LIFESCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA SUVEN LIFESCIENCES NATCO PHARMA/
SUVEN LIFESCIENCES
 
P/E (TTM) x 15.5 19.8 78.6% View Chart
P/BV x 3.0 4.0 76.1% View Chart
Dividend Yield % 1.5 0.5 277.6%  

Financials

 NATCO PHARMA   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
SUVEN LIFESCIENCES
Mar-19
NATCO PHARMA/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs1,080338 319.8%   
Low Rs671169 396.3%   
Sales per share (Unadj.) Rs592.152.1 1,135.8%  
Earnings per share (Unadj.) Rs188.46.8 2,758.2%  
Cash flow per share (Unadj.) Rs206.38.6 2,407.7%  
Dividends per share (Unadj.) Rs8.251.50 550.0%  
Dividend yield (eoy) %0.90.6 159.3%  
Book value per share (Unadj.) Rs833.665.3 1,276.8%  
Shares outstanding (eoy) m36.90127.28 29.0%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.54.9 30.4%   
Avg P/E ratio x4.637.1 12.5%  
P/CF ratio (eoy) x4.229.6 14.3%  
Price / Book Value ratio x1.13.9 27.0%  
Dividend payout %4.422.0 19.9%   
Avg Mkt Cap Rs m32,31132,272 100.1%   
No. of employees `0004.81.1 446.5%   
Total wages/salary Rs m3,256661 492.4%   
Avg. sales/employee Rs Th4,522.56,132.2 73.7%   
Avg. wages/employee Rs Th674.0611.1 110.3%   
Avg. net profit/employee Rs Th1,439.0803.5 179.1%   
INCOME DATA
Net Sales Rs m21,8486,635 329.3%  
Other income Rs m404242 166.7%   
Total revenues Rs m22,2526,877 323.6%   
Gross profit Rs m9,2841,604 578.7%  
Depreciation Rs m662221 299.0%   
Interest Rs m15438 408.5%   
Profit before tax Rs m8,8721,587 558.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,920718 267.4%   
Profit after tax Rs m6,952869 799.6%  
Gross profit margin %42.524.2 175.8%  
Effective tax rate %21.645.2 47.8%   
Net profit margin %31.813.1 242.8%  
BALANCE SHEET DATA
Current assets Rs m21,3076,232 341.9%   
Current liabilities Rs m5,9201,490 397.3%   
Net working cap to sales %70.471.5 98.5%  
Current ratio x3.64.2 86.1%  
Inventory Days Days7386 84.7%  
Debtors Days Days10783 128.9%  
Net fixed assets Rs m14,9864,043 370.6%   
Share capital Rs m369127 289.9%   
"Free" reserves Rs m30,3538,183 370.9%   
Net worth Rs m30,7608,310 370.2%   
Long term debt Rs m018 0.0%   
Total assets Rs m37,15110,389 357.6%  
Interest coverage x58.643.1 136.0%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.6 92.1%   
Return on assets %19.18.7 219.1%  
Return on equity %22.610.5 216.0%  
Return on capital %29.319.5 150.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,3225,622 183.6%   
Fx outflow Rs m2,9781,799 165.5%   
Net fx Rs m7,3433,822 192.1%   
CASH FLOW
From Operations Rs m4,636356 1,304.1%  
From Investments Rs m-11,155-279 4,003.9%  
From Financial Activity Rs m6,509-225 -2,891.6%  
Net Cashflow Rs m-18-148 12.1%  

Share Holding

Indian Promoters % 52.0 63.4 82.1%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 0.0 -  
FIIs % 16.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 36.5 71.2%  
Shareholders   25,395 37,287 68.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   WYETH LTD  IPCA LABS  JUBILANT LIFE SCIENCES  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend, Developments From the IPO Space, and Top Cues in Focus Today(Pre-Open)

On Tuesday, Indian share markets fell sharply during closing hours amid fears of rising crude oil prices and weakness in the rupee.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 17, 2019 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS